Author Archives: Santiago Gisler

Millendo Starts Phase 2b/3 Study Evaluating Livoletide as PWS Treatment

Millendo Therapeutics has launched a Phase 2b/3 clinical trial investigating the safety and efficacy of livoletide (AZP-531) in patients with Prader-Willi syndrome (PWS), the company announced. The rare genetic disease is characterized by hyperphagia (excessive eating) and obesity, caused by abnormal hormonal levels. Livoletide is designed to reduce…

Inhibition, Working Memory Impaired in PWS Patients, Study Finds

Impairments in behavioral and working memory tasks are seen in people with Prader-Willi syndrome (PWS) compared with healthy controls, a new study shows. The study, “Investigation of the relationship between electrodermal and behavioural responses to executive tasks in Prader-Willi syndrome: An event-related experiment,” was published in the journal…